Gut bacteria linked to Alzheimer’s risk
A compound produced by gut bacteria appears to be closely linked to a higher risk of Alzheimer’s disease. It promotes the build-up of harmful brain proteins and is associated with faster cognitive decline. The findings suggest the gut plays an active role in dementia development.
Researchers identified a molecule called imidazole propionate (ImP), produced by certain gut bacteria when breaking down the amino acid histidine. The study found that higher ImP levels in the blood were associated with greater accumulation of amyloid plaques and tau proteins in the brain. Both are hallmarks of Alzheimer’s disease.
The findings are associative at this stage: the study demonstrates a correlation, not a causal relationship. Still, the association is striking. People with higher ImP concentrations also showed faster decline in memory and other cognitive functions. From a longevity perspective, this is notable because it points to a potential new target outside the brain itself.
From gut to brain
The idea that gut bacteria influence the brain through their metabolic products is known as the gut-brain axis. Gut bacteria continuously produce compounds that reach the entire body via the bloodstream. ImP is one such compound. Earlier research had already linked ImP to insulin resistance and inflammation, two processes also implicated in Alzheimer’s.
The researchers suggest that lowering ImP levels in the blood could potentially have a protective effect. How that might work in practice remains unclear. Possible routes include dietary adjustments or selectively influencing the bacteria that produce ImP. This remains speculative and requires further investigation.
A new direction in dementia research
Alzheimer’s research has traditionally focused on the brain itself: clearing plaques, inhibiting tau phosphorylation, protecting neurons. This research adds a different layer. If a bacterial byproduct in the gut genuinely contributes to brain deterioration, it opens doors for early blood-based diagnostics and for prevention through microbiome composition.
It is important to keep the findings in perspective. The study is based on correlations in a human population. Whether reducing ImP also slows cognitive decline must be demonstrated in future research.
Search terms to explore further: gut-brain axis Alzheimer’s | imidazole propionate cognition | microbiome amyloid plaques